Agilent Presents Solutions Innovation Research Awards to Institut National de la Recherche Scientifique and University of Southern California Scientists
06 Novembre 2024 - 2:00PM
Business Wire
Professor Isabelle Plante and Professor Bangyan Stiles
recognized for their revolutionary work in cell and gene therapy
research
Agilent Technologies Inc. (NYSE: A) today announced that
Professor Isabelle Plante at Institut National de la Recherche
Scientifique (INRS), and Professor Bangyan Stiles at the University
of Southern California (USC) are recipients of an Agilent Solutions
Innovation Research Award (SIRA). The honorees will receive
separate awards on behalf of their institutions in recognition of
their research in cell and gene therapy.
Developing new cell and gene therapies is increasingly vital
amid the heightened focus on personalized treatments in the
healthcare industry. In recognition of this growing need, Agilent
will grant two SIRA awards to support and encourage research to
drive critical breakthroughs in cell and gene therapy.
“We are thrilled to recognize the groundbreaking research of
Professor Isabelle Plante and Professor Bangyan Stiles with an
Agilent Solutions Innovation Research Award,” said Nahid Chalyavi,
associate vice president of University Relations and External
Research at Agilent. “Their work in cell and gene therapy is paving
the way for significant advancements in personalized medicine. At
Agilent, we are committed to supporting innovative research that
addresses critical scientific challenges and drives the future of
healthcare.”
Professor Plante is a Professor at INRS and the Director and
Co-founder of the Intersectoral Centre for Endocrine Disruptor
Analysis (ICEDA) research network. Her work aims to understand the
biology of the breast and the mechanisms that lead to breast
cancer, particularly after exposure to environmental pollutants. To
achieve this, Professor Plante has developed a platform of models
for fundamental and toxicological research, and for evaluating the
effects of therapeutic agents on the breast. The study involves
using proteomic, transcriptomic, and functional analysis to assess
the impacts of pollutants or therapeutic molecules combined with
imaging. Professor Plante will receive a one-year loan of Agilent
NovoCyte Penteon, BioTek Cytation 5, and xCelligence instruments as
part of the award.
“On average, 15 women lose their lives to breast cancer each
day. While the exact causes of breast cancer remain largely
unknown, a growing body of epidemiological and laboratory evidence
suggests that exposure to environmental pollutants increases the
risk. Given the vast number of potentially carcinogenic molecules
present in our environment, there is an urgent need to develop
biologically relevant models for rapid risk assessment and to
explore new therapeutic avenues,” stated Professor Plante. “We
extend our heartfelt thanks to Agilent for this invaluable
opportunity to co-develop new models and methodologies that will
help prevent and treat breast cancer, potentially saving many
lives.”
Professor Stiles is the Boyd P. and Elsie D. Welin Professor of
Pharmaceutical Sciences in the Department of Pharmacology and
Pharmaceutical Sciences at USC Mann. Her work focuses on
understanding how lipid metabolic dysfunction contributes to cancer
formation, using hepatocellular carcinoma as a model, indicates
that fat accumulation is necessary for tumor growth. Professor
Stiles’ lab utilizes molecular biology and genetics tools,
including Chip-seq and RNA-seq, to investigate the molecular
signals driving this process. As part of Professor Stiles’ award,
the lab will receive a one-year loan of an Agilent NovoCyte Penteon
flow cytometer.
“I am deeply honored to receive the Agilent Solutions Innovation
Research Award, which supports our lab’s mission to understand how
lipid metabolic dysfunction contributes to cancer formation,”
stated Professor Stiles. “Our work, using hepatocellular carcinoma
as a model, has shown that fat accumulation is critical for tumor
growth. With the loan of an Agilent NovoCyte Penteon flow
cytometer, we’re now equipped to explore the cellular components in
the tumor microenvironment that are responsible for how fat
accumulation contribute to cancer growth. This award strengthens
our commitment to pioneering research that could lead to
transformative treatments in personalized medicine.”
Established in 2023, the Agilent SIRA initiative aims to
stimulate innovative and impactful use of Agilent products to help
solve pressing scientific problems in academia. The awards
reinforce Agilent’s commitment to facilitating university research
and increasing awareness of and access to its portfolio of
analytical solutions.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.85 billion in fiscal 2022 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241106140731/en/
Media Contact Naomi Goumillout Agilent Technologies
+1.978.314.1862 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024